BP897 | CAS# 314776-92-6 | D3 receptor compound

MedKoo Cat#: 530471 | Name: BP897

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

BP897 is a potent (K(i) = 0.92 nM) dopamine D(3) receptor compound developed for the treatment of cocaine abuse and craving. BP 897 has a high selectivity for the dopamine D(3) versus D(2) receptors (70-fold) and a moderate affinity for 5-HT(1A) receptors, (K(i) = 84 nM), adrenergic-alpha(1) (K(i) = 60 nM) and -alpha(2) adrenoceptors (K(i) = 83 nM). BP 897 displays significant intrinsic activity at the human dopamine D(3) receptor by decreasing forskolin-stimulated cAMP levels and by stimulating mitogenesis of dopamine D(3)-expressing NG108-15 cells.

Chemical Structure

BP897

CAS# 314776-92-6

Theoretical Analysis

MedKoo Cat#: 530471

Name: BP897

CAS#: 314776-92-6

Chemical Formula: C26H31N3O2

Exact Mass: 417.2416

Molecular Weight: 417.55

Elemental Analysis: C, 74.79; H, 7.48; N, 10.06; O, 7.66

Price and Availability

Size	Price	Availability
50mg	USD 450.00	2 Weeks
100mg	USD 750.00	2 Weeks
200mg	USD 1,250.00	2 Weeks
500mg	USD 2,450.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

BP897; BP-897; BP 897;

IUPAC/Chemical Name

N-(4-(4-(2-methoxyphenyl)piperazin-1-yl)butyl)-2-naphthamide

InChi Key

MNHDKMDLOJSCGN-UHFFFAOYSA-N

InChi Code

InChI=1S/C26H31N3O2/c1-31-25-11-5-4-10-24(25)29-18-16-28(17-19-29)15-7-6-14-27-26(30)23-13-12-21-8-2-3-9-22(21)20-23/h2-5,8-13,20H,6-7,14-19H2,1H3,(H,27,30)

SMILES Code

O=C(NCCCCN1CCN(C2=CC=CC=C2OC)CC1)C3=CC=C4C=CC=CC4=C3

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 417.55 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Zhou B, Hong KH, Ji M, Cai J. Design, synthesis, and biological evaluation of structurally constrained hybrid analogues containing ropinirole moiety as a novel class of potent and selective dopamine D3 receptor ligands. Chem Biol Drug Des. 2018 Sep;92(3):1597-1609. doi: 10.1111/cbdd.13324. Epub 2018 Jul 1. PMID: 29710404. 2: Zhou B, Ji M, Cai J. Design, synthesis and biological evaluation of bitopic arylpiperazine-hexahydro-pyrazinoquinolines as preferential dopamine D3 receptor ligands. Bioorg Chem. 2018 Apr;77:125-135. doi: 10.1016/j.bioorg.2017.12.026. Epub 2018 Jan 9. PMID: 29353729. 3: Schübler M, Sadek B, Kottke T, Weizel L, Stark H. Synthesis, Molecular Properties Estimations, and Dual Dopamine D2 and D3 Receptor Activities of Benzothiazole-Based Ligands. Front Chem. 2017 Sep 12;5:64. doi: 10.3389/fchem.2017.00064. PMID: 28955709; PMCID: PMC5601007. 4: Nebel N, Maschauer S, Kuwert T, Hocke C, Prante O. In Vitro and In Vivo Characterization of Selected Fluorine-18 Labeled Radioligands for PET Imaging of the Dopamine D3 Receptor. Molecules. 2016 Aug 29;21(9):1144. doi: 10.3390/molecules21091144. PMID: 27589704; PMCID: PMC6272905. 5: Hocke C, Cumming P, Maschauer S, Kuwert T, Gmeiner P, Prante O. Biodistribution studies of two 18F-labeled pyridinylphenyl amides as subtype selective radioligands for the dopamine D3 receptor. Nucl Med Biol. 2014 Mar;41(3):223-8. doi: 10.1016/j.nucmedbio.2013.12.014. Epub 2013 Dec 26. PMID: 24480780. 6: Sokoloff P, Leriche L, Diaz J, Louvel J, Pumain R. Direct and indirect interactions of the dopamine D₃ receptor with glutamate pathways: implications for the treatment of schizophrenia. Naunyn Schmiedebergs Arch Pharmacol. 2013 Feb;386(2):107-24. doi: 10.1007/s00210-012-0797-0. Epub 2012 Sep 22. PMID: 23001156; PMCID: PMC3558669. 7: Tadori Y, Forbes RA, McQuade RD, Kikuchi T. Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors. Eur J Pharmacol. 2009 Apr 1;607(1-3):35-40. doi: 10.1016/j.ejphar.2009.02.007. Epub 2009 Feb 13. PMID: 19217900. 8: Tadori Y, Forbes RA, McQuade RD, Kikuchi T. Characterization of aripiprazole partial agonist activity at human dopamine D3 receptors. Eur J Pharmacol. 2008 Nov 12;597(1-3):27-33. doi: 10.1016/j.ejphar.2008.09.008. Epub 2008 Sep 20. PMID: 18831971. 9: Gao M, Wang M, Hutchins GD, Zheng QH. Synthesis of new carbon-11-labeled carboxamide derivatives as potential PET dopamine D3 receptor radioligands. Appl Radiat Isot. 2008 Dec;66(12):1891-7. doi: 10.1016/j.apradiso.2008.05.010. Epub 2008 Jul 3. PMID: 18602269. 10: Spiller K, Xi ZX, Peng XQ, Newman AH, Ashby CR Jr, Heidbreder C, Gaál J, Gardner EL. The selective dopamine D3 receptor antagonists SB-277011A and NGB 2904 and the putative partial D3 receptor agonist BP-897 attenuate methamphetamine-enhanced brain stimulation reward in rats. Psychopharmacology (Berl). 2008 Mar;196(4):533-42. doi: 10.1007/s00213-007-0986-6. Epub 2007 Nov 6. PMID: 17985117; PMCID: PMC3713235. 11: Preti A. New developments in the pharmacotherapy of cocaine abuse. Addict Biol. 2007 Jun;12(2):133-51. doi: 10.1111/j.1369-1600.2007.00061.x. PMID: 17508985. 12: Millan MJ, Iob L, Péglion JL, Dekeyne A. Discriminative stimulus properties of S32504, a novel D3/D2 receptor agonist and antiparkinson agent, in rats: attenuation by the antipsychotics, aripiprazole, bifeprunox, N-desmethylclozapine, and by selective antagonists at dopamine D2 but not D3 receptors. Psychopharmacology (Berl). 2007 Apr;191(3):767-82. doi: 10.1007/s00213-006-0567-0. Epub 2006 Sep 19. PMID: 17047933. 13: Narendran R, Slifstein M, Guillin O, Hwang Y, Hwang DR, Scher E, Reeder S, Rabiner E, Laruelle M. Dopamine (D2/3) receptor agonist positron emission tomography radiotracer [11C]-(+)-PHNO is a D3 receptor preferring agonist in vivo. Synapse. 2006 Dec 1;60(7):485-95. doi: 10.1002/syn.20325. PMID: 16952157. 14: Visanji NP, Millan MJ, Brotchie JM. Actions at sites other than D(3) receptors mediate the effects of BP897 on l-DOPA-induced hyperactivity in monoamine-depleted rats. Exp Neurol. 2006 Nov;202(1):85-92. doi: 10.1016/j.expneurol.2006.05.016. Epub 2006 Jun 30. PMID: 16814282. 15: Gál K, Gyertyán I. Dopamine D3 as well as D2 receptor ligands attenuate the cue-induced cocaine-seeking in a relapse model in rats. Drug Alcohol Depend. 2006 Jan 4;81(1):63-70. doi: 10.1016/j.drugalcdep.2005.05.011. Epub 2005 Jul 7. PMID: 16005579. 16: Gilbert JG, Newman AH, Gardner EL, Ashby CR Jr, Heidbreder CA, Pak AC, Peng XQ, Xi ZX. Acute administration of SB-277011A, NGB 2904, or BP 897 inhibits cocaine cue-induced reinstatement of drug-seeking behavior in rats: role of dopamine D3 receptors. Synapse. 2005 Jul;57(1):17-28. doi: 10.1002/syn.20152. PMID: 15858839; PMCID: PMC3726034. 17: Polakowski JS, Segreti JA, Cox BF, Hsieh GC, Kolasa T, Moreland RB, Brioni JD. Effects of selective dopamine receptor subtype agonists on cardiac contractility and regional haemodynamics in rats. Clin Exp Pharmacol Physiol. 2004 Dec;31(12):837-41. doi: 10.1111/j.1440-1681.2004.04095.x. PMID: 15659045. 18: Laszy J, Laszlovszky I, Gyertyán I. Dopamine D3 receptor antagonists improve the learning performance in memory-impaired rats. Psychopharmacology (Berl). 2005 May;179(3):567-75. doi: 10.1007/s00213-004-2096-z. Epub 2004 Dec 24. PMID: 15619116. 19: Francès H, Le Foll B, Diaz J, Smirnova M, Sokoloff P. Role of DRD3 in morphine-induced conditioned place preference using drd3-knockout mice. Neuroreport. 2004 Oct 5;15(14):2245-9. doi: 10.1097/00001756-200410050-00021. PMID: 15371743. 20: Johnston TH, Brotchie JM. Drugs in development for Parkinson's disease. Curr Opin Investig Drugs. 2004 Jul;5(7):720-6. PMID: 15298067.